drugset / Trial / NCT07624201
Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer
Phase 2
Not yet recruiting
58 enrolled
Harbin Medical University
First Hospital of China Medical University · collabJilin Provincial Tumor Hospital · collabThe Fourth Affiliated Hospital of China Medical University · collabTianjin Medical University Second Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of neoadjuvant trastuzumab rezetecan combined with adebrelimab for the treatment of HER2-positive muscle-invasive bladder cancer.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2028-06-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | 3.2 mg/kg | — |